Fulgent Genetics, Inc.
FLGT
$28.48
$0.080.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.18% | 15.17% | 13.92% | 8.10% | -15.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.18% | 15.17% | 13.92% | 8.10% | -15.28% |
| Cost of Revenue | 7.97% | 6.36% | 6.46% | -2.01% | 0.29% |
| Gross Profit | 32.65% | 29.99% | 28.24% | 26.24% | -32.81% |
| SG&A Expenses | 16.30% | 29.27% | 10.76% | -19.73% | 8.73% |
| Depreciation & Amortization | 1.61% | 0.00% | 0.00% | 1.74% | 1.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.93% | 12.88% | 8.08% | -8.92% | 5.15% |
| Operating Income | 10.12% | -4.27% | 9.19% | 47.76% | -8,080.84% |
| Income Before Tax | 59.48% | -91.89% | 17.29% | 94.46% | -370.15% |
| Income Tax Expenses | 82.20% | -6.54% | 153.82% | 82.92% | -118.88% |
| Earnings from Continuing Operations | 53.55% | -111.84% | 14.06% | 95.39% | -9.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 373.91% | -21.32% | -3.91% | -95.12% | -87.19% |
| Net Income | 54.89% | -117.65% | 14.35% | 95.41% | -11.76% |
| EBIT | 10.12% | -4.27% | 9.19% | 47.76% | -8,080.84% |
| EBITDA | 16.55% | -7.10% | 8.32% | 59.17% | -268.23% |
| EPS Basic | 55.38% | -114.44% | 17.29% | 95.54% | -10.28% |
| Normalized Basic EPS | 15.55% | -3.27% | 20.72% | 51.25% | -211.30% |
| EPS Diluted | 55.38% | -114.00% | 17.29% | 95.52% | -9.45% |
| Normalized Diluted EPS | 15.55% | -3.27% | 20.72% | 51.25% | -211.30% |
| Average Basic Shares Outstanding | 1.09% | 1.48% | 3.57% | 2.96% | 1.34% |
| Average Diluted Shares Outstanding | 1.09% | 1.48% | 3.57% | 2.96% | 1.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |